A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making — Pascale Guitera (2025) | RDL Network
A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making
Article 2025 en
Authors
PG
Pascale Guitera
SL
Serigne Lo
JS
Jonathan R. Stretch
Abstract
1 min read
Imiquimod represents a substantially more cost-effective treatment option for managing LM compared with radiotherapy. Patient-centered shared decision-making should be prioritized.
Angela Hong, Serigne Lo, Gerald B. Fogarty, Jonathan R. Stretch, Wei Wang, Pablo Fernández‐Peñas, Richard C. Martin, Matthew Foote, H. Peter Soyer, Jeremy Ruben, Victoria Mar, Lílian Rocha, Christopher Wratten, Helena Collgros, Amanda Pereira, Bruna Melhoranse Gouveia, Richard A Scolyer, Madeleine King, Pascale Guitera
Pascale Guitera, Andréanne Waddell, Elizabeth Paton, Gerald B. Fogarty, Angela Hong, Richard A Scolyer, Jonathan R. Stretch, Brett O’Donnell, Giovanni Pellacani
Pascale Guitera, Andréanne Waddell, Elizabeth Paton, Gerald B. Fogarty, Angela Hong, Richard A Scolyer, Jonathan R. Stretch, Brett O’Donnell, Giovanni Pellacani
Mitchell Robinson, Clare Primiero, Pascale Guitera, Angela Hong, Richard A Scolyer, Jonathan R. Stretch, Geoffrey Strutton, John F. Thompson, H. Peter Soyer
Discussion(0)
No comments yet. Be the first to comment.